SearchLight DNA™ Success Stories

Aubie

SearchLight DNA® Testing Revealed Treatment Strategies for Aggressive Osteosarcoma:

SearchLight DNA testing revealed 7 mutation biomarkers and two therapeutic options, including a PALB2 mutation that can predict sensitivity to platinum-based chemotherapy combined with PARP inhibition.

Many genes can influence prognosis, our panel covers a wider range of mutations associated with clinical outcomes.

Precision medicine is about targeting specific mutations with tailored therapies, our panel significantly expands the possibilities for personalized treatment strategies for our dogs.

Lotus

SearchLight DNA® Results Incorporated Into Urothelial Carcinoma Treatment:

Lotus, a 7-year-old Basset Hound, was diagnosed with Urothelial Carcinoma in February 2024 after months of diagnostic tests.

A SearchLight DNA testing revealed BRAF mutation with sensitivities to MEK inhibitors.

Trametinib was recommended and incorporated into ongoing vinblastine treatment which has resulted in stabilization of the disease.

Lotus has been responding well and has experienced no side effects with the combination therapy.

Tenney

SearchLight DNA Testing Revealed Treatment Strategies for Aggressive Osteosarcoma:

A SearchLight DNA test revealed 9 mutations and two lines of targeted therapy options.

Olaparib (PARP inhibitor) and carboplatin were implemented as a first-line therapeutic approach resulting in remission and far exceeded the expected survival seen with a carboplatin regimen alone.

SearchLight DNA analysis is especially helpful to guide treatment strategies with aggressive cancers such as osteosarcoma

Remmy

SearchLight DNA® Reveals BRAF Point Mutation:

Remmy, a vibrant young Doberman Pinscher, had a mass along the hard palate that was histologically identified as a poorly differentiated neoplasm.

A SearchLight DNA test revealed a BRAF point mutation, suggesting sensitivity to multiple targeted therapies including trametinib.

In Remmy’s case, SearchLight DNA was able to give a therapeutic indication based on a mutation identified within the tumor, even though the mutation is usually associated with other tumor types.

Remmy’s tumor experienced significant shrinkage with trametinib, and Remmy did not have any side effects associated with this drug.

Nira

SearchLight DNA® Guides Treatment Planning:

A 10-year-old golden retriever named Nira was diagnosed with histiocytic sarcoma. After completing an initial course of radiation therapy, medical treatment with cobimetinib was started based on literature suggesting the tumor could bear KRAS and PTPN11 mutations, which are associated with response to cobimetinib.

SearchLight DNA test revealed the absence of KRAS or PTPN11 mutations along with the presence of a mutation that suggested cobimetinib resistance. The treatment plan was switched to only radiation therapy and sirolimus.

In Nira’s case, SearchLight DNA provided valuable data that informed her treatment plan.